Health Watch USA Logo Health Watch USA – Infection Control Today

Infection Control Today
Back To COVID-19 HW USA Infection Control Today Page 

28.  Eli Lilly Neutralizing Antibodies: Breakthrough for COVID-19 Treatment?
Eli Lilly announced preliminary results to their SARS-CoV-2 neutralizing antibody product, LY-CoV555, which was reported to have spectacular results with a 72% decrease in hospitalizations or ER visits when mildly or moderately symptomatic patients are given the drug within 3 days of diagnosis.
As observed in the Eli Lilly study, those newly diagnosed patients who are obese or have advanced age are the most likely to become hospitalized, and I feel initially this innovative product should be targeted toward these high-risk patients.  Infection Control Today.  Sept. 17, 2020.    Download Original Article

Updated Oct. 8, 2020.


(1) Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting. News Release. Sept. 16, 2020. 

(2) Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs. News Release. Oct. 7, 2020. 

(3) Spinner CD, Gottlieb SR, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial. JAMA. Aug. 21, 2020. 

(4) Strathdee S and Patterson T. The Perfect Predator: A Scientist's Race to Save Her Husband from a Deadly Superbug: A Memoir. Sept. 17, 2020.

This webpage is for guidance only, always consult your healthcare provider and the a href="" target="_blank"> CDC Website for information before making decisions relating to the coronavirus.